Angeles Wealth Management LLC Buys 3,830 Shares of Merck & Co., Inc. (NYSE:MRK)

by · The Markets Daily

Angeles Wealth Management LLC raised its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 14.0% during the third quarter, HoldingsChannel reports. The institutional investor owned 31,242 shares of the company’s stock after acquiring an additional 3,830 shares during the period. Angeles Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $3,548,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in MRK. Itau Unibanco Holding S.A. bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter valued at about $39,000. Abich Financial Wealth Management LLC boosted its position in shares of Merck & Co., Inc. by 121.8% during the 2nd quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after purchasing an additional 179 shares in the last quarter. Quarry LP bought a new stake in shares of Merck & Co., Inc. during the 2nd quarter valued at about $42,000. Mowery & Schoenfeld Wealth Management LLC boosted its position in shares of Merck & Co., Inc. by 47.5% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock valued at $43,000 after purchasing an additional 122 shares in the last quarter. Finally, Reston Wealth Management LLC bought a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at about $43,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Down 0.4 %

Shares of Merck & Co., Inc. stock traded down $0.44 on Friday, hitting $101.88. The company had a trading volume of 10,180,978 shares, compared to its average volume of 9,562,252. The stock has a market capitalization of $258.04 billion, a price-to-earnings ratio of 21.36, a P/E/G ratio of 1.46 and a beta of 0.40. Merck & Co., Inc. has a 1 year low of $98.60 and a 1 year high of $134.63. The stock has a 50 day moving average of $112.29 and a 200-day moving average of $120.84. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.22 and a current ratio of 1.47.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $1.50 by $0.07. The firm had revenue of $16.66 billion during the quarter, compared to the consensus estimate of $16.47 billion. Merck & Co., Inc. had a return on equity of 37.32% and a net margin of 19.23%. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.13 earnings per share. As a group, sell-side analysts forecast that Merck & Co., Inc. will post 7.76 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Truist Financial cut their target price on Merck & Co., Inc. from $143.00 to $132.00 and set a “buy” rating on the stock in a research report on Wednesday, October 9th. Bank of America cut their target price on Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Barclays dropped their price target on Merck & Co., Inc. from $142.00 to $140.00 and set an “overweight” rating on the stock in a research note on Monday, October 7th. UBS Group dropped their price target on Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating on the stock in a research note on Wednesday, October 9th. Finally, Morgan Stanley dropped their price target on Merck & Co., Inc. from $130.00 to $123.00 and set an “equal weight” rating on the stock in a research note on Friday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus price target of $129.93.

Read Our Latest Report on MRK

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).